Product Document Searching Made Easy by 2D Code! | TCI Chemistry News June 2026 | [TCIPracticalExample] Oxidation Reaction of Heterocycles Using... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 52214-84-3 | Product Number: C2667
Ciprofibrate
×
Purity: >98.0%(GC)(T)
Synonyms:
- 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropionic Acid
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 1G |
$29.00
|
1 | 0 | It can be shipped in about 2 weeks after ordering | |
| 5G |
$91.00
|
1 | 0 | It can be shipped in about 2 weeks after ordering |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | C2667 |
Purity / Analysis Method 
|
>98.0%(GC)(T) |
| Molecular Formula / Molecular Weight | C__1__3H__1__4Cl__2O__3 = 289.15 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container
|
1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 52214-84-3 |
| Reaxys Registry Number | 1984981 |
| PubChem Substance ID | 160871346 |
| Merck Index (14) | 2313 |
| MDL Number | MFCD00467135 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(GC) | min. 98.0 % |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 116.0 to 120.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 118 °C |
| Solubility (soluble in) | Methanol |
GHS
Related Laws:
| RTECS# | UF0880000 |
Transport Information:
| H.S.code* | 2918.99-000 |
Application
Clofibrate: Antilipemic with Activity against Peroxisome Proliferator-Activated Receptors (PPARs)
The fibrates, including ciprofibrate, are lower elevated serum lipids by decreasing the low density lipoprotein (LDL) fraction rich in cholesterol and the very low density lipoprotein (VLDL) fraction rich in triglycerides. In addition, fibrates increase the high density lipoprotein (HDL) cholesterol fraction. The precise mechanisms of action remain unknown, but it has been reported that the major modes of action of the fibrates as follows: VLDL catabolism by increased lipoprotein and hepatic triglyceride lipase activities; suppression of triglyceride biosynthesis by acetyl-CoA carboxylase enzyme inhibition and attenuation of cholesterol biosynthesis by inhibition of the rate-limiting HMG-CoA reductase.
Since the late 1990s, it has been reported that fibrates activate specific transcription factors belonging to the nuclear hormone receptor superfamily, termed peroxisome proliferator-activated receptors (PPARs) which activation increases HDL cholesterol synthesis, stimulates "reverse" cholesterol transport and reduces triglycerides. (The product is for research purpose only.)
Since the late 1990s, it has been reported that fibrates activate specific transcription factors belonging to the nuclear hormone receptor superfamily, termed peroxisome proliferator-activated receptors (PPARs) which activation increases HDL cholesterol synthesis, stimulates "reverse" cholesterol transport and reduces triglycerides. (The product is for research purpose only.)
References
- Mechanism of action of fibrates on lipid and lipoprotein metabolism (a review)
- The peroxisome proliferator-activated receptor α-selective activator ciprofibrate upregulates expression of genes encoding fatty acid oxidation and ketogenesis enzymes in rat brain
- Liver gene expression in rats in response to the peroxisome proliferator-activated receptor-α agonist ciprofibrate
- Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography
Application
Studies on Peroxisome Proliferator-Activated Receptors (PPARs)
References
- Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ
- Mechanism of action of fibrates on lipid and lipoprotein metabolism
- Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity
PubMed Literature
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Enter TCI Product Number
Enter KISHIDA Product Number
4-5 alphanumeric characters before the hyphen
7 alphanumeric characters
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
• The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
• Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
• If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
• Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
The requested analytical chart is not available. Sorry for the inconvenience.